Finanzen von Embecta Corp (EMBC)EMBCEmbecta Corp

Embecta Corp. (EMBC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pen Needles, accounting for 65.3% of total sales, equivalent to $177.50M. Other significant revenue streams include Safety and Syringes. Understanding this composition is critical for investors evaluating how EMBC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Embecta Corp. maintains a gross margin of 55.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 23.67%, while the net margin is 7.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively EMBC converts its operational activities into shareholder value.

In the context of the broader market, EMBC competes directly with industry leaders such as ANIK and CV. With a market capitalization of $296.33M, it holds a significant position in the sector. When comparing efficiency, EMBC's gross margin of 55.47% stands against ANIK's 65.15% and CV's 51.36%. Such benchmarking helps identify whether Embecta Corp. is trading at a premium or discount relative to its financial performance.

Embecta reported a net income of $21 million in Q3 2026, but has seen a significant decline in revenue, with a 14.4% year-over-year drop in sales for Q2 2026. The gross margin has also decreased to 55.47% in Q3 2026, down from 65.99% in Q3 2025, reflecting operational challenges.